The first half of 2018 has seen the announcement of high-profile and potentially transformative transactions, including in the healthcare and telecommunications sectors. I say “potentially” because, among other things, the transactions are still subject to regulatory review. This, along with recent court decisions, has thrust antitrust enforcement regimes, especially as they relate to merger review, back in the spotlight. Indeed, some would say that antitrust never left the spotlight, but those people are probably antitrust attorneys.
Premium Content For:
- Current ABA Member